Market closedNon-fractional
PMV Pharmaceuticals/PMVP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About PMV Pharmaceuticals
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Ticker
PMVP
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Princeton, United States
Employees
63
Website
www.pmvpharma.com
PMVP Metrics
BasicAdvanced
$85M
Market cap
-
P/E ratio
-$1.32
EPS
1.55
Beta
-
Dividend rate
Price and volume
Market cap
$85M
Beta
1.55
Financial strength
Current ratio
16.791
Quick ratio
16.416
Long term debt to equity
5.709
Total debt to equity
6.123
Management effectiveness
Return on assets (TTM)
-19.41%
Return on equity (TTM)
-29.40%
Valuation
Price to book
0.4
Price to tangible book (TTM)
0.4
Price to free cash flow (TTM)
-1.401
Growth
Earnings per share change (TTM)
-18.73%
3-year earnings per share growth (CAGR)
-5.57%
What the Analysts think about PMVP
Analyst Ratings
Majority rating from 6 analysts.
PMVP Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
-3.18%
Profit margin
0.00%
NaN%
PMVP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.34
-$0.31
-$0.30
-
Expected
-$0.48
-$0.45
-$0.39
-$0.36
-$0.35
Surprise
-20.00%
-23.77%
-19.69%
-16.78%
-
PMVP News
AllArticlesVideos
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Business Wire·2 months ago
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
GlobeNewsWire·2 months ago
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PMV Pharmaceuticals stock?
PMV Pharmaceuticals (PMVP) has a market cap of $85M as of July 27, 2024.
What is the P/E ratio for PMV Pharmaceuticals stock?
The price to earnings (P/E) ratio for PMV Pharmaceuticals (PMVP) stock is 0 as of July 27, 2024.
Does PMV Pharmaceuticals stock pay dividends?
No, PMV Pharmaceuticals (PMVP) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next PMV Pharmaceuticals dividend payment date?
PMV Pharmaceuticals (PMVP) stock does not pay dividends to its shareholders.
What is the beta indicator for PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell PMV Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.